Amgen Inc. (AMGN) Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024 (Transcript)
Amgen Inc. (AMGN) Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024 (Transcript)
Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships
Nvidia Corp. NVDA, +4.72% is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships Monday with Amgen Inc. AMGN, +1.26% and Recursion Phar...
7 Rock-Solid Healthcare Dividend Stocks to Buy in January
The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preve...
Why the Market Dipped But Amgen (AMGN) Gained Today
Amgen (AMGN) reachead $303.17 at the closing of the latest trading day, reflecting a +0.82% change compared to its last close.
January Dogs Of The Dow: 2 Buyable, 6 Watchable
"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration....
Revenge of the Boring Stocks! Dividends Are Sexy Again.
It's a new year and apparently there's a new theme on Wall Street for investors. Many of the Magnificent Seven stocks and their high-flying tech peers are off to a difficult start in 2024.
Amgen analysts boost target price on obesity drug data outlook
Amgen Inc (NASDAQ:AMGN, ETR:AMG) stock is poised to move higher in 2024 on a thesis its Phase II drug AMG133 for obesity will report positive data, according to Jefferies analysts. In an update t...
Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Amgen (AMGN) closed at $286.53, marking a +0.93% move from the previous day.
Obesity drug enthusiasm can continue in 2024: Mizuho's Jared Holz
Mizuho's Jared Holz joins 'Fast Money' to talk enthusiasm surrounding obesity drugs and if that can endure into 2024.
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
Amgen's NDA for Lumakras cancer treatment resulted in complete response letter
Amgen Inc. AMGN said Tuesday that the regulatory review of its supplemental new drug application seeking full approval of Lumakras resulted in a “complete response letter” from the U.S. Food and Dr...
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone'
Investors in search of high-risk, high-reward investments can often find them among the top biotech stocks to buy. Identifying worthwhile opportunities can be easier said than done when investing i...
Can Dogs of the Dow ETFs Snap Losing Trend in 2024?
The Dogs of the Dow in 2023 are up an average of just 2.8%, lagging the market by the widest amount since 2006, per Bespoke Investment Group, as quoted on Investors Business Daily. But more importa...
Amgen Stock Rises After Analyst Praises Pipeline
BMO upgraded Amgen, Inc. (NASDAQ:AMGN) to "outperform" from "market perform" earlier, and hiked its price objective to $326 from $286, implying 18.3% upside to its last close.
Amgen shares rise as analysts see ‘value obesity play'
Shares of Amgen Inc. AMGN, +0.01% gained 1.1% premarket on Tuesday after BMO Capital Markets analysts upgraded the stock to outperform, from market perform, citing the company's “underappreciated” ...
Related Companies